US 2023 AF Guideline

The US 2023 atrial fibrillation (AF) guideline emphasizes a rhythm control strategy and highlight the need for lifestyle and risk factor modification in addition to medical treatment. Key points including: The new proposed classification of AF by 4 stages, recognizes AF as a disease continuum that requires a variety of strategies at the different stages. Risk factor management throughout the disease continuum and offers more prescriptive recommendations for lifestyle and risk factor modification as a pillar of AF management to prevent onset, progression, and adverse outcomes. Flexibility in using clinical risk scores and expanding beyond CHA₂DS₂-VASc for prediction of stroke and systemic embolism. Consideration of factors that might modify risk of stroke. The importance of early and continued management of patients with AF that should focus on maintaining sinus rhythm and minimizing AF burden. Catheter ablation of AF receives a Class 1 indication as first-line therapy in selected patients, including appropriate patients with heart failure with reduced ejection fraction. Recommendations have been updated for device-detected AF that consider the interaction between episode duration and the patient’s underlying risk for thromboembolism. Left atrial appendage occlusion devices receive Class 2a recommendation in patients with long-term contraindications to anticoagulation. Recommendations are made for patients with AF identified during medical illness or surgery (precipitants). Source: https://www.jacc.org/